Skip to main content
SpringerLink
Log in

Prospective Clinical Trials of Brain Tumor Therapy: The Critical Role of Neurosurgeons

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Prospective clinical trials are critical to the scientific evaluation of new treatments for brain tumors. This paper reviews basic concepts of early and late phase prospective clinical trials that are most relevant to neurosurgical oncologists, with an emphasis on the challenges associated with conducting clinical trials of brain tumor therapies. Novel clinical trial designs that meet these challenges by incorporating pretreatment “molecular profiling” and post-treatment “molecular endpoints” are described. Because of their ability to obtain brain tumor specimens from patients before and after treatment, neurosurgeons have been required to play an increasingly important role in the execution of these molecular-based clinical trials. Potential avenues for enhancing the participation of neurosurgeons in the design and development of clinical trials are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Haines SJ: Evidence-based neurosurgery. Neurosurgery 52: 36–47, 2003

    PubMed  Google Scholar 

  2. Walker MD, Green SB, Byar DP, Alexander Jr, E, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley Jr, MS, Mealey Jr, J, Owens G, Ransohoff J, 2nd, Robertson JT, Shapiro WR, Smith Jr, KR, Wilson CB, Strike TA: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303: 1323–329, 1980

    CAS  PubMed  Google Scholar 

  3. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83: 588–593, 2000

    CAS  PubMed  Google Scholar 

  4. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O’Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17: 2762–2771, 1999

    CAS  PubMed  Google Scholar 

  5. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold SC: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymerbrain Tumor Treatment Group. Lancet 345: 1008–1012, 1995

    CAS  PubMed  Google Scholar 

  6. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jaaskelainen J, Ram Z: A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU)wafers (Gliadel wafers)in patients with primary malignant glioma. Neurooncol 5: 79–88, 2003

    CAS  Google Scholar 

  7. Nazzaro JM, Neuwelt EA: The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. J Neurosurg 73: 331–344, 1990

    PubMed  Google Scholar 

  8. Hentschel SJ, Lang FF: Current surgical management of glioblastoma. Cancer J 9: 113–125, 2003

    PubMed  Google Scholar 

  9. Lang FF, Gilbert MR, Puduvalli VK, Weinberg J, Levin VA, Yung WK, Sawaya R, Fuller GN, Conrad CA: Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies. Neurooncol 4: 268–277, 2002

    CAS  Google Scholar 

  10. Chang SM, Barker FG, Schmidt MH, Sloan AE, Kasper R, Phillips L, Shih K, Hariharan S, Berger MS: Clinical Trial Participation Among Patients Enrolled in the Glioma Outcomes Project. Cancer 94: 2681–2687, 2002

    PubMed  Google Scholar 

  11. Asher AL, Anderson F, Stolzenbach K, Barker F, Limentani S, Laws E: Preoperative Differences Between Community and Academic Medical Centers in the Glioma Outcomes Project. Fourth Biennial Brain Tumor Satellite Symposium, San Francisco, CA, 2000

  12. Warnick ER, Raffel C, Glick RP: Neurooncology Research Opportunities in North America: Results of a Survey by the AANS/CNS Section on Tumors. J Neurooncol 61: 197–201, 2003

    PubMed  Google Scholar 

  13. Chalmers TC: The clinical trail. Milbank Memor Fund Quart/Health Society 59: 324–339, 1981

    CAS  Google Scholar 

  14. Friedman LM, Furberg CD, DeMets DL: Introduction to Clinical Trials. In: Friedman L, Furberg C, DeMets D (eds) Fundamentals of Clinical Trials (Third Edition). Mosby-Year Book, Inc, St. Louis, 1996, pp 1–15

    Google Scholar 

  15. Friedman LM, Furberg CD, DeMets DL: Fundamentals of Clinical Trials (Third Edition). Mosby-Year Book, Inc, St Loius, 1996

    Google Scholar 

  16. Spriet A, Dupin-Spriet T, Simon P: Methodology of Clinical Drug Trials (First English Edition). S. Karger, France, 1985

    Google Scholar 

  17. Spilker B: Guide to Clinical Trials. Raven Press, New York, 1991

    Google Scholar 

  18. Ginsberg D: The Investigator’s Guide to Clinical Research. Center Watch, Inc, Boston, 1999

    Google Scholar 

  19. Cancer Therapeutic Evaluation Program Common Terminology Criteria for Adverse Events v3.0., Published December 12, 2003, http://ctep.cancer.gov, 2003

  20. O’Quigley J, Pepe M, Fisher L: Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 46: 33–48, 1990

    CAS  PubMed  MathSciNet  Google Scholar 

  21. Storer BE: Design and analysis of phase I clinical trials. Biometrics 45: 925–937, 1989

    CAS  PubMed  MathSciNet  Google Scholar 

  22. O’Quigley J, Chevret S: Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study. Stat Med 10: 1647–1664, 1991

    CAS  PubMed  Google Scholar 

  23. Armitage P: The role of randomization in clinical trials. Stat Med 1: 345–352, 1982

    CAS  PubMed  Google Scholar 

  24. Byar DP, Simon RM, Friedewald WT, Schlesselman JJ, DeMets DL, Ellenberg JH, Gail MH, Ware JH: Randomized clinical trials. Perspectives on some recent ideas. N Engl J Med 295: 74–80, 1976

    CAS  PubMed  Google Scholar 

  25. Pocock SJ: Allocation of patients to treatment in clinical trials. Biometrics 35: 183–197, 1979

    CAS  PubMed  Google Scholar 

  26. Spilker B: Randomization procedures. In: Spilker B (ed) Guide to Clinical Trials. Raven Press, New York, 1991, pp 69–73

    Google Scholar 

  27. Freedman B: Equipoise and the ethics of clinical research. N Engl J Med 317: 141–145, 1987

    CAS  PubMed  Google Scholar 

  28. Spilker B: Statistical issues. In: Spilker B (ed) Guide to Clinical Trials. Raven Press, New York, 1991, pp 497–501

    Google Scholar 

  29. Fisher L, Van Belle G: Biostatistics-A Methodology for the Health Sciences. John Wiley & Sons, New York, 1993

    Google Scholar 

  30. Crowley J: Handbook of Statistics in Clinical Oncology. Marcel Dekker, Inc, New York, 2001

    Google Scholar 

  31. Gehan EA: Methodological issues in cancer clinical trials: the comparison of therapies. Biomed Pharmacother 42: 161–165, 1988

    CAS  PubMed  Google Scholar 

  32. Lachin JM: Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials 2: 93–113, 1981

    CAS  PubMed  Google Scholar 

  33. Davis B, Hardy R: Upper bounds for type I and type II error rates in conditional power calculations. Commun. Stat. Theor. Meth. 19: 3571–3584, 1991

    Google Scholar 

  34. Friedman L, Furberg C, DeMets DL: Sample size. In: Friedman L, Furberg C, DeMets DL (eds) Fundamentals of Clinical Trials (Third Edition). Mosby-Year Book, St. Louis, 1996, pp 94–129

    Google Scholar 

  35. Code of Federal Regulations, Title 21-Food and Drugs Revised as of April 1, 2003 U. S. Government Printing Offce Parts 50 (Protection of Human Subjects) 56 (Institutional Review Boards) 312 (Investigational New Drug Application) http://www.access.gpo.gov/cgibin/cfrassemble.cgi, 2003

  36. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). E6: Good Clinical Practice consolidated Guideline. http://www.ich.org/, 1996

  37. Association of Clinical Research Professionals, Good Clinical Practices for Clinical Investigators. http://www.acrpnet.org/education/gcp/index.html, 2002

  38. Nuremberg Code. Trials of War Criminals before the Nuremberg Military Tribunals under Control Council Law No. 10. Washington, DC, U. S. Government Printing Office, 1949, pp 181–182

  39. World Medical Association, Declaration of Helsinki, Ethical Principals for Medical Research Involving Human Subjects. Adopted 1964, Revised 1975, 1983, 1989, 1996 http://www.wma.net/e/policy/b3.htm, 2000

  40. The Belmont Report. Ethical Principles and Guidelines for the Protection of Human Subjects of Research. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. http: //ohsr.od.nih.gov/mpa/belmont.php3, 1979

  41. Food and Drug Administration Guidance for Institutional Review Boards and Clinical Investigators. http://www.fda.gov/oc/ohrt/irbs/default.htm, 1998

  42. Gilbert MR: Brain tumor clinical trials: pitfalls and promise for the future. Curr Oncol Rep 2: 473–475, 2000

    CAS  PubMed  Google Scholar 

  43. Kaplan RS: Complexities, pitfalls, and strategies for evaluating brain tumor therapies. Curr Opin Oncol 10: 175–178, 1998

    CAS  PubMed  Google Scholar 

  44. Vaporciyan A, Swisher S: Thoracic Malignancies. In: Feig BW, Berger DH, Fuhrman GM (eds) The M. D. Anderson Surgical Oncology Handbook (Third Edition). Lippincott Williams & Wilkins, Philadelphia, 2003, pp 124–144

    Google Scholar 

  45. CBTRUS: Statistical Report: Primary Brain Tumors in the United States 1995–1999. Central Brain Tumor Registry of the United States, Chicago, 2002, pp 9–10

    Google Scholar 

  46. Kleihues P, Burger PC, Collins VP, Newcomb EW, Ohgaki H, Cavenee WK: Glioblastoma. In: Kleihues P, Cavenee WK (eds) Pathology & Genetics of Tumours of the Nervous System. IARC Press, Lyon, France, 2000, pp 29–39

    Google Scholar 

  47. Kim TS, Halliday AL, Hedley-Whyte ET, Convery K: Correlates of survival and the Daumas-Duport grading system for astrocytomas. J Neurosurg 74: 27–37, 1991

    CAS  PubMed  Google Scholar 

  48. Gilbert MR, Supko JG, Batchelor T, Lesser G, Fisher JD, Piantadosi S, Grossman S: Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 9: 2940–2949, 2003

    CAS  PubMed  Google Scholar 

  49. Dowlati A, Haaga J, Remick SC, Spiro TP, Gerson SL, Liu L, Berger SJ, Berger NA, Willson JK: Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin Cancer Res 7: 2971–2976, 2001

    CAS  PubMed  Google Scholar 

  50. Eisenhauer EA: Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16–19 June 1998. Ann Oncol 9: 1047–1052, 1998

    CAS  PubMed  Google Scholar 

  51. Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P: Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst 91: 1281–1287, 1999

    CAS  PubMed  Google Scholar 

  52. Macdonald DR, Cascino TL, Schold Jr, SC, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277–1280, 1990

    CAS  PubMed  Google Scholar 

  53. Giglio P, Gilbert MR: Cerebral radiation necrosis. Neurolog 9: 180–188, 2003

    Google Scholar 

  54. Kumar AJ, Leeds NE, Fuller GN, Van Tassel P, Maor MH, Sawaya RE, Levin VA: Malignant gliomas: MR imaging spectrum of radiation therapy-and chemotherapy-induced necrosis of the brain after treatment. Radiology 217: 377–384, 2000

    CAS  PubMed  Google Scholar 

  55. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100: 57–70, 2000

    CAS  PubMed  Google Scholar 

  56. Louis DN, Holland EC, Cairncross JG: Glioma classification: a molecular reappraisal. Am J Pathol 159: 779–786, 2001

    CAS  PubMed  Google Scholar 

  57. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C, Jr.: Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12: 2013–2021, 1994

    CAS  PubMed  Google Scholar 

  58. Lang FF, Bruner JM, Fuller GN, Aldape K, Prados MD, Chang S, Berger MS, McDermott MW, Kunwar SM, Junck LR, Chandler W, Zwiebel JA, Kaplan RS, Yung WK: Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 21: 2508–2518, 2003

    CAS  PubMed  Google Scholar 

  59. Hess KR, Wong ET, Jaeckle KA, Kyritsis AP, Levin VA, Prados MD, Yung WK: Response and progression in recurrent malignant glioma. Neurooncol 1: 282–288, 1999

    CAS  Google Scholar 

  60. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH: Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 91: 2076–2080, 1994

    CAS  PubMed  Google Scholar 

  61. Rules and Regulations of the Joint Section on Tumors of the American Association of Neurological Surgeons and the Congress of Neurological Surgeons, 1997, pp 1–15

  62. Solomon MJ, McLeod RS: Should we be performing more randomized controlled trials evaluating surgical operations? Surgery 118: 459–467, 1995

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery and The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Department of Neurosurgery, Unit 442, 1515 Holcombe Boulevard, Houston, TX, 77030, USA

    Frederick F. Lang

  2. Carolina Neurosurgery & Spine Associates, Charlotte, NC, USA

    Anthony Asher

Authors
  1. Frederick F. Lang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anthony Asher
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lang, F.F., Asher, A. Prospective Clinical Trials of Brain Tumor Therapy: The Critical Role of Neurosurgeons. J Neurooncol 69, 151–167 (2004). https://doi.org/10.1023/B:NEON.0000041878.93045.f5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:NEON.0000041878.93045.f5

Search

Navigation